Study included 309 newly diagnosed and previously untreated CLL patients.
Characterstics: Median age: 71 years Binet A/B/C: 79/12/9% Unmutated IGHV genes: 35% Clonal TP53/NOTCH1/SF3B1/BIRC3 lesions: 11/11/7/5% Median follow-up: 8.1 years; TP53 mutations: screened on peripheral blood.
Deep-NGS identified 50 subclonal TP53 mutations in 9% of the population.
TP53 mutations reported : Subclonal only: 4.8% Subclonal TP53 mutations with a clonal TP53 mutation or 17p deletion: (4.2%)
Median overall survival: Sole subclonal TP53 mutation : 3.4 years . TP53 wild type cases :10.8 years Clonal TP53 genetic defects:3.1 years.
Subclonal TP53 mutations :multivariate analysis showed increased hazard of death (HR: 2.0; p=.023).
Small TP53 mutated subclones detected in significant fraction of patients.
Deep-NGS to search for minor subclones of TP53 disruption should be considered in assessment of CLL patients.
- In newly diagnosed CLL patients, study assessed significance of small TP53 mutated subclones in frequency, prognostic impact and volution of disease.
View the original abstract on the ASH website.
